Targeting Tumor‐Associated Exosomes with Integrin‐Binding Peptides. Issue 5 (3rd April 2017)

• Record Type: Journal Article
• Authors: Carney, Randy P.; Hazari, Sidhartha; Rojalin, Tatu; Knudson, Alisha; Gao, Tingjuan; Tang, Yuchen; Liu, Ruiwu; Viitala, Tapani; Yliperttula, Marjo; Lam, Kit S.
• Is Part Of: Advanced biosystems. Volume 1 :Issue 5 (2017)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-04-03
• Subjects: biosensors -- cancer -- diagnostics -- exosomes -- optical tweezers; Biological systems -- Periodicals; Biotechnology -- Periodicals; Bioengineering -- Periodicals; Biomedical engineering -- Periodicals; Biological Science Disciplines; Periodicals; Periodicals; 660.6
• DOI: 10.1002/adbi.201600038
• Languages: English
• ISSNs: 2366-7478

Abstract

Abstract : All cells expel a variety of nanosized extracellular vesicles (EVs), including exosomes, with composition reflecting the cells' biological state. Cancer pathology is dramatically mediated by EV trafficking via key proteins, lipids, metabolites, and microRNAs. Recent proteomics evidence suggests that tumor‐associated exosomes exhibit distinct expression of certain membrane proteins, rendering those proteins as attractive targets for diagnostic or therapeutic application, yet it is not currently feasible to distinguish circulating EVs in complex biofluids according to their tissue of origin or state of disease. Here, peptide binding to tumor‐associated EVs via overexpressed membrane protein is demonstrated. It is found that SKOV‐3 ovarian tumor cells and their released EVs express α3 β1 integrin, which can be targeted by the in‐house cyclic nonapeptide, LXY30. After measuring bulk SKOV‐3 EV association with LXY30 by flow cytometry, Raman spectral analysis of laser‐trapped single exosomes with LXY30‐dialkyne conjugate enables the differentiation of cancer‐associated exosomes from noncancer exosomes. Furthermore, the foundation for a highly specific detection platform for tumor‐EVs in solution with biosensor surface‐immobilized LXY30 is introduced. LXY30 not only exhibits high specificity and affinity to α3 β1 integrin‐expressing EVs, but also reduces EV uptake into SKOV‐3 parent cells, demonstrating the possibility for therapeutic application. Abstract : Specific peptides are excellent candidates as binding agents for circulating extracellular vesicles (EVs), and therefore have great potential for cancer detection. Using a variety of analytical tools, including real‐time surface capture, the affinity and specificity of one such agent, a small cyclic peptide called LXY30, toward surface protein present predominantly on ovarian cancer cell released EVs are demonstrated.